On Thursday, Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), gained 18.72% to $2.41.
Ampio Pharmaceuticals, Inc., declared positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controlled, parallel, double masked study to evaluate the safety and efficacy of two doses of oral Optina (adjusted to body mass index-BMI) in adult patients with Diabetic Macular Edema (DME).
The OptimEyes trial, with FDA guidance, was designed to comprise a wide variety of DME patients, some of whom had no therapeutic options and were progressing to blindness. Intraocular injections may have been contraindicated in these patients. Counting patients not accepted in other trials of intraocular injections allowed us to better understand the effect of oral Optina in improving visual acuity (measured as best corrected visual acuity-BCVA, eye chart) and reducing edema (as measured by optical coherence tomography-OCT) in all patients.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States.
Shares of Tyson Foods, Inc. (NYSE:TSN), inclined 0.16% to $43.49, during its last trading session.
Executives from Tyson Foods, told investors at the BMO Farm to Market conference that the company is plannedally diversified because it combines branded consumer products, commodity protein production and prepared foods and value-added chicken for the food service industry.
“Tyson Foods is in a preferred position and a unique position,” Donnie Smith, president and chief executive officer, said. “We have the protein consumers want to eat, and we have the #1 brands in those categories. We have the research and development expertise and consumer insights behind those #1 brands to keep driving innovation. We have the raw materials to make those innovative products, and we’re a food company that’s growing.”
“Our aim is to deliver top-tier performance in the food industry,” said Andy Callahan, president of retail packaged brands. “We have an advantaged portfolio with a preferred position to grow ahead of the competition. Our brand building model has a proven track record of growth, and our new product pipeline is robust.”
Tyson Foods, Inc., together with its auxiliaries, produces, distributes, and markets chicken, beef, pork, prepared foods, and related allied products worldwide. The company breeds and raises chickens; and processes live chickens into fresh, frozen, and value-added chicken products.
At the end of Thursday’s trade, Shares of Stem Cells Inc (NASDAQ:STEM), gained 1.34% to $0.6131.
StemCells, Inc., declared that administration will make a presentation on the Company’s programs, pipeline and operations at the 2015 Marcum MicroCap Conference. Administration is planned to speak at 1:30 p.m. Eastern Daylight Time on Thursday, May 28, at The Grand Hyatt New York Hotel, in the Imperial room, located at 109 E 42nd Street in New York City.
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development.
Finally, Marsh & McLennan Companies, Inc. (NYSE:MMC), ended its last trade with -0.03% gained, and closed at $59.10.
Marsh & McLennan Companies, Inc. (MMC) held its annual meeting of shareholders at which the Company declared that its Board of Directors voted to enhance both the Company’s quarterly cash dividend and share repurchase program.
The Board of Directors raised the quarterly cash dividend by 11% from $.28 to $.31 per share on outstanding common stock. The dividend is payable on August 14, 2015 to shareholders of record on July 10, 2015.
Marsh & McLennan Companies, Inc., a professional services firm, provides advice and solutions primarily in the areas of risk, strategy, and people worldwide. It operates in two segments, Risk and Insurance Services; and Consulting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
